One System. Infinite Parameters.

The Brain’s Last Barrier —

and How Low-Intensity Focused Ultrasound Can Open It

Low-intensity focused ultrasound · Microbubbles · Targeted drug delivery

The blood-brain barrier is one of the body’s most sophisticated defense systems. A dense network of tightly packed cells lining the brain’s blood vessels, it shields neural tissue from pathogens, toxins, and foreign molecules — including most therapeutic drugs.

For decades, this barrier has been medicine’s most frustrating obstacle. Treatments that work elsewhere in the body simply can’t reach the brain in meaningful concentrations. Systemic drug flooding, surgical implants, and chemical workarounds have all fallen short — either too imprecise, too invasive, or too risky.

Low-intensity focused ultrasound (LIFU), combined with microbubbles, changes the equation entirely.

Microbubbles are microscopic gas-filled spheres — smaller than a red blood cell — injected into the bloodstream before treatment. When focused ultrasound reaches them at the target site, they oscillate rapidly, gently massaging the vessel walls and loosening the tight junctions of the blood-brain barrier at precisely the right location. The effect is highly localized, controllable, and amplified — microbubbles allow the barrier to open at significantly lower acoustic energy levels than ultrasound alone, reducing stress on surrounding tissue.

The window opens. The drug passes through. Then the barrier closes again, naturally, within hours.

No incisions. No systemic toxicity. No permanent disruption.

The result is a delivery mechanism that is simultaneously more targeted than any surgical approach and less invasive than a standard infusion — opening new possibilities for treating brain tumors, Alzheimer’s disease, Parkinson’s disease, epilepsy, and beyond.

Brain tumors · Alzheimer’s disease · Parkinson’s disease · Epilepsy

Purpose-Built for Research Rigor

Open-LIFU's programmable architecture lets researchers define and iterate on sonication protocols with fine-grained control over frequency, pressure, and timing — enabling systematic, reproducible studies of BBB opening dynamics. Whether you're optimizing microbubble parameters, characterizing spatial selectivity, or mapping the relationship between acoustic dose and barrier permeability, Open-LIFU provides the experimental flexibility that off-the-shelf systems simply can't match.

Transparent, Accessible Data

Open access to raw channel data and system telemetry means your team can build, validate, and publish custom analysis pipelines — keeping your research methodology fully transparent and peer-reviewable.

A Platform That Grows With Your Science

Open-LIFU is under active development, with a roadmap shaped by the needs of the research community. Cavitation detection — a critical safety and monitoring capability for BBB work — is on the near-term roadmap, positioning Open-LIFU to support increasingly sophisticated closed-loop experimental designs as the field advances.

Open-LIFU is intended for research use only and has not received regulatory clearance for clinical applications.

Engineered for the Clinic. Exceptional in the Lab.

Most pre-clinical research tools are built for the bench and stop there. Open-LIFU is different. Designed from the ground up to the engineering standards of a medical device, Open-LIFU brings clinical-grade rigor to the research environment — and that distinction matters.

Research That Translates

The gap between promising pre-clinical results and viable clinical application is often as much an engineering problem as a scientific one. When your research platform is architected to the same standards as the device that will eventually reach patients, the translational path becomes dramatically shorter. Findings generated on Open-LIFU are findings generated on a system built to scale — meaning your protocols, parameters, and safety characterizations carry real weight as you move toward clinical development.

Medical Device Engineering as a Research Advantage

Clinical-grade engineering isn't just about what happens downstream — it makes Open-LIFU a better research tool today. Tighter hardware tolerances, robust calibration workflows, and rigorous system validation mean the acoustic outputs you specify are the outputs you get. That level of fidelity is foundational to reproducible science and credible publication.

A Single Platform Across the Development Continuum

From first-in-animal studies through IND-enabling work and into clinical investigation, Open-LIFU is designed to accompany your program every step of the way. Rather than transitioning to an entirely new system as your work matures — and re-validating everything that comes with it — Open-LIFU offers continuity of platform, continuity of data, and continuity of confidence.

Open-LIFU is intended for research use only and has not received regulatory clearance for clinical applications.

Pharmaceutics · 2025

What happens after the door opens?

Arsiwala et al. · West Virginia University

Opening the blood-brain barrier is only half the story — what happens next matters just as much. This study found that a single session of low-intensity focused ultrasound (LiFUS) doesn’t create just one window of opportunity: it triggers a two-phase opening of the barrier over time. Researchers tracked downstream effects on drug transporter proteins and inflammation in both treated and untreated brain regions, offering a clearer roadmap for timing drug delivery after ultrasound treatment — a critical step toward making this technology clinically precise.

Read full article →

Journal of Neuro-Oncology · 2024

Unlocking glioblastoma: what the clinical trials tell us

Zhu et al. · King’s College London

Glioblastoma is one of the deadliest brain cancers — and the blood-brain barrier is a major reason treatments fail. This systematic review examined clinical trials using focused ultrasound combined with microbubbles to temporarily breach that barrier and boost drug delivery directly to tumors. The approach proved non-invasive, targeted, and reversible, with microbubbles amplifying the ultrasound effect at the barrier wall. The review maps where the evidence is strongest, where gaps remain, and what the field needs to push toward broader clinical use.

Read full article →

Neuro-Oncology · 2024

Beyond ultrasound alone: a consensus on breaking the barrier

Piper et al. · Moffitt Cancer Center

A multidisciplinary team reviewed the full landscape of strategies designed to get drugs past the blood-brain barrier in CNS tumor patients. Among emerging technologies, low-intensity focused ultrasound stood out for its ability to temporarily and safely increase barrier permeability — no surgery required. While most LIFU advances are still in animal models, the authors highlight a growing pipeline of translational clinical trials expected to report results in the coming years, signaling that a tipping point in clinical adoption may be near.

Read full article →